Daniel O’cOnnell
Research Subjects
Research Interests
Daniel O’cOnnell has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Daniela A Bota
Department of Neurology, University of California, IrvineOr Medical Center, Orange, CA, USA
1 shared publicationViolet Shen
Department of Neurology, University of California, IrvineOr Medical Center, Orange, CA, USA
1 shared publicationWilliam Loudon
Department of Neurology, University of California, IrvineOr Medical Center, Orange, CA, USA
1 shared publication
Latest Publications
- 5 December 2016
- Published by Taylor & Francis in CNS Oncology
- Vol. 6 (1) , 11-18
First report of tumor treating fields use in combination with bevacizumab in a pediatric patient: a case report
We report the first case of a pediatric patient with glioblastoma (GBM; WHO grade IV astrocytoma) successfully treated with tumor treating fields (TTF). The patient was diagnosed with GBM when 13 years of age and progressed through surgical resection, radiotherapy and chemotherapy. Discrete tumor growth visualized on MRI with stable neurological examination was monitored for 6 months with subsequent stable disease observed radiographically and clinically for 7 months while adherent to Optune® (TTF). TTF thereby played a role in forestalling recurrent GBM growth in this young woman for 7 months without significant adverse effects. We propose that TTF therapy is a potential valuable treatment in this small, but sick, patient population.
- 5 December 2016
- Published by Taylor & Francis in CNS Oncology
- Vol. 6 (1) , 11-18
First report of tumor treating fields use in combination with bevacizumab in a pediatric patient: a case report
We report the first case of a pediatric patient with glioblastoma (GBM; WHO grade IV astrocytoma) successfully treated with tumor treating fields (TTF). The patient was diagnosed with GBM when 13 years of age and progressed through surgical resection, radiotherapy and chemotherapy. Discrete tumor growth visualized on MRI with stable neurological examination was monitored for 6 months with subsequent stable disease observed radiographically and clinically for 7 months while adherent to Optune® (TTF). TTF thereby played a role in forestalling recurrent GBM growth in this young woman for 7 months without significant adverse effects. We propose that TTF therapy is a potential valuable treatment in this small, but sick, patient population.